2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

Alunno, A, Najm, A, Machado, PM et al. (21 more authors) (2021) 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases. ISSN 0003-4967

Abstract

Metadata

Authors/Creators:
  • Alunno, A
  • Najm, A
  • Machado, PM
  • Bertheussen, H
  • Burmester, G-RR
  • Carubbi, F
  • De Marco, G ORCID logo https://orcid.org/0000-0003-2406-161X
  • Giacomelli, R
  • Hermine, O
  • Isaacs, JD
  • Koné-Paut, I
  • Magro-Checa, C
  • McInnes, IB
  • Meroni, PL
  • Quartuccio, L
  • Ramanan, AV
  • Ramos-Casals, M
  • Rodríguez Carrio, J
  • Schulze-Koops, H
  • Stamm, TA
  • Tas, SW
  • Terrier, B
  • McGonagle, DG
  • Mariette, X
Copyright, Publisher and Additional Information: © Author(s) (or their employer(s)) 2021. This is an author produced version of an article published in Annals of the Rheumatic Diseases (ARD). Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Covid-19; biological therapy; glucocorticoids
Dates:
  • Accepted: 29 September 2021
  • Published (online): 7 October 2021
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 02 Nov 2021 13:43
Last Modified: 02 Nov 2021 13:43
Status: Published online
Publisher: BMJ Publishing Group
Identification Number: https://doi.org/10.1136/annrheumdis-2021-221366
Related URLs:

Share / Export

Statistics